Literature DB >> 25946058

Transcatheter tricuspid valve-in-valve in patients with transvalvular device leads.

Mackram F Eleid1, Samuel J Asirvatham1, Allison K Cabalka2, Donald J Hagler2, Peter A Noseworthy1, Nathaniel W Taggart2, Charanjit S Rihal1.   

Abstract

OBJECTIVE: To describe the effects of percutaneously implanted valve-in-valve in the tricuspid position for patients with pre-existing transvalvular device leads.
METHODS: In this case series, we describe implantation of the Melody valve and SAPIEN XT valve within dysfunctional bioprosthetic tricuspid valves in three patients with transvalvular device leads.
RESULTS: In all cases, the valve was successfully deployed and device lead function remained unchanged. In 1/3 cases with 6-month follow-up, device lead parameters remain unchanged and transcatheter valve-in-valve function remains satisfactory.
CONCLUSIONS: Transcatheter tricuspid valve-in-valve is feasible in patients with pre-existing transvalvular devices leads. Further study is required to determine the long-term clinical implications of this treatment approach.
© 2015 Wiley Periodicals, Inc.

Entities:  

Keywords:  percutaneous valve therapy; structural heart disease intervention; transcatheter valve implantation

Mesh:

Year:  2015        PMID: 25946058     DOI: 10.1002/ccd.25990

Source DB:  PubMed          Journal:  Catheter Cardiovasc Interv        ISSN: 1522-1946            Impact factor:   2.692


  2 in total

1.  First-in-human combined transcatheter tricuspid valve implantation with leadless VDD pacemaker via left internal jugular approach.

Authors:  Benjamin W Hale; David J Bradley; Jeffrey D Zampi; Wendy Whiteside; Ryan Cunnane
Journal:  HeartRhythm Case Rep       Date:  2021-11-26

Review 2.  Transcatheter treatment by valve-in-valve and valve-in-ring implantation for prosthetic tricuspid valve dysfunction.

Authors:  Varius Dannenberg; Carolina Donà; Matthias Koschutnik; Max-Paul Winter; Christian Nitsche; Andreas A Kammerlander; Philipp E Bartko; Christian Hengstenberg; Julia Mascherbauer; Georg Goliasch
Journal:  Wien Klin Wochenschr       Date:  2021-03-31       Impact factor: 1.704

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.